用于减轻残余心血管风险的糖尿病血脂异常的新型且有前景的治疗方法。
Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk.
作者信息
Jialal Ishwarlal, Gounden Verena
机构信息
Department of Pathology and Internal Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Department of Clinical Biochemistry, University Hospital Galway, H91 YR71 Galway, Ireland.
出版信息
J Clin Med. 2024 Aug 20;13(16):4915. doi: 10.3390/jcm13164915.
Abstract
Diabetes is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), and the dyslipidemia of diabetes is pivotal in the genesis of this leading cause of increased morbidity and mortality that burdens diabetic patients [...].
摘要
糖尿病是动脉粥样硬化性心血管疾病（ASCVD）的主要危险因素，糖尿病血脂异常在这一导致糖尿病患者发病率和死亡率增加的主要病因的发生过程中起关键作用。
相似文献
1
Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk.用于减轻残余心血管风险的糖尿病血脂异常的新型且有前景的治疗方法。
J Clin Med. 2024 Aug 20;13(16):4915. doi: 10.3390/jcm13164915.
2
Current Practices and Gaps in Management of Dyslipidemia in Type 2 Diabetes Mellitus (T2DM) in Accordance with American Diabetes Association (ADA) Guidelines: A Subset Analysis from a Real-World, Cross-Sectional Observational Study (LEADD Study).根据美国糖尿病协会（ADA）指南，2型糖尿病（T2DM）患者血脂异常管理的现状与差距：一项来自真实世界横断面观察性研究（LEADD研究）的亚组分析
Diabetes Metab Syndr Obes. 2021 Jun 15;14:2693-2700. doi: 10.2147/DMSO.S294842. eCollection 2021.
3
Management of diabetic dyslipidemia: An update.糖尿病血脂异常的管理：最新进展
World J Diabetes. 2019 May 15;10(5):280-290. doi: 10.4239/wjd.v10.i5.280.
4
Mechanisms and Treatment of Dyslipidemia in Diabetes.糖尿病血脂异常的发病机制与治疗。
Curr Cardiol Rep. 2021 Mar 2;23(4):26. doi: 10.1007/s11886-021-01455-w.
5
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data.聚焦阿利西尤单抗用于伴有2型糖尿病和混合性血脂异常的高心血管风险患者：对新出现数据的综述
Diabetes Metab Syndr Obes. 2019 Sep 19;12:1897-1911. doi: 10.2147/DMSO.S167375. eCollection 2019.
6
Characteristics of patients with dyslipidemia treated in routine care setting in China.中国常规护理环境下血脂异常患者的特征。
J Drug Assess. 2019 Oct 23;8(1):192-198. doi: 10.1080/21556660.2019.1684926. eCollection 2019.
7
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.优化血脂异常管理以预防心血管疾病：关注风险评估和治疗选择。
Curr Cardiol Rep. 2019 Aug 5;21(9):110. doi: 10.1007/s11886-019-1175-z.
8
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents.女性动脉粥样硬化性心血管疾病：使用调脂药物提供保护
Clin Ther. 2023 Nov;45(11):1127-1136. doi: 10.1016/j.clinthera.2023.08.021. Epub 2023 Sep 26.
9
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.阿利西尤单抗治疗 2 型糖尿病合并动脉粥样硬化性心血管疾病患者：ODYSSEY DM-DYSLIPIDEMIA 和 DM-INSULIN 研究分析。
Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9.
10
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.降低欧洲剩余心血管风险：欧洲药品管理局批准依泽替米贝/二十碳五烯酸的治疗意义。
Pharmacol Ther. 2022 Sep;237:108172. doi: 10.1016/j.pharmthera.2022.108172. Epub 2022 Mar 15.
引用本文的文献
1
Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials.奥雷扎森治疗血脂异常的疗效和安全性：随机对照试验的系统评价和剂量反应荟萃分析
J Saudi Heart Assoc. 2025 Jun 12;37(3):3. doi: 10.37616/2212-5043.1439. eCollection 2025.
本文引用的文献
1
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.Zodasiran，一种针对 ANGPTL3 的 RNAi 治疗药物，用于治疗混合性高脂血症。
N Engl J Med. 2024 Sep 12;391(10):913-925. doi: 10.1056/NEJMoa2404147. Epub 2024 May 29.
2
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.Olezarsen 治疗心血管疾病高危患者的高三酰甘油血症。
N Engl J Med. 2024 May 16;390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7.
3
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.Plozasiran（ARO-APOC3）治疗严重高甘油三酯血症：SHASTA-2 随机临床试验。
JAMA Cardiol. 2024 Jul 1;9(7):620-630. doi: 10.1001/jamacardio.2024.0959.
4
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?糖尿病患者的血脂异常：新一代治疗方法有何特别考虑？
Diabetologia. 2024 Jun;67(6):974-984. doi: 10.1007/s00125-024-06100-z. Epub 2024 Feb 20.
5
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.血脂异常治疗的进展：聚焦于载脂蛋白C3和血管生成素样蛋白3抑制剂
J Lipid Atheroscler. 2024 Jan;13(1):2-20. doi: 10.12997/jla.2024.13.1.2. Epub 2023 Oct 27.
6
Lipoprotein(a): from Causality to Treatment.脂蛋白(a)：从因果关系到治疗。
Curr Atheroscler Rep. 2024 Mar;26(3):75-82. doi: 10.1007/s11883-024-01187-6. Epub 2024 Jan 22.
7
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.贝匹地酸在有糖尿病和无糖尿病患者中的疗效和安全性：CLEAR Outcomes 随机试验的预设分析。
Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28. doi: 10.1016/S2213-8587(23)00316-9. Epub 2023 Dec 4.
8
Lipid-lowering in diabetes: An update.糖尿病患者的降脂治疗：最新进展。
Atherosclerosis. 2024 Jul;394:117313. doi: 10.1016/j.atherosclerosis.2023.117313. Epub 2023 Oct 6.
9
Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events.贝派地酸，一种胆固醇生物合成抑制剂，可降低心血管事件发生率。
J Clin Med. 2023 May 14;12(10):3463. doi: 10.3390/jcm12103463.
10
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.贝匹地酸在他汀类药物不耐受患者中的心血管结局。
N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4.
Zotero 插件